Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden ; volume:11 ; number:12 ; day:6 ; month:10 ; year:2020 ; pages:2921-2930 ; date:12.2020
Diabetes therapy ; 11, Heft 12 (6.10.2020), 2921-2930, 12.2020
- Urheber
-
Bernfort, Lars
Husberg, Magnus
Wiréhn, Ann-Britt
Rosenqvist, Ulf
Gustavsson, Staffan
Karlsdotter, Kristina
Levin, Lars-Åke
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-020-00937-4
- URN
-
urn:nbn:de:101:1-2020121818382051580981
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bernfort, Lars
- Husberg, Magnus
- Wiréhn, Ann-Britt
- Rosenqvist, Ulf
- Gustavsson, Staffan
- Karlsdotter, Kristina
- Levin, Lars-Åke
- SpringerLink (Online service)
Ähnliche Objekte (12)
Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
Societal costs of fetal alcohol syndrome in Sweden
Governance strategy and costs: board compensation in Sweden
The societal costs of problem gambling in Sweden
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study
Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung
Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
Societal costs of fetal alcohol syndrome in Sweden
Governance strategy and costs: board compensation in Sweden
The societal costs of problem gambling in Sweden
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study
Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung
Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
Societal costs of fetal alcohol syndrome in Sweden
Governance strategy and costs: board compensation in Sweden
The societal costs of problem gambling in Sweden
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study